SEP-363856: Ph II SEP361-203 started

Sumitomo Dainippon’s Sunovion Pharmaceuticals Inc. subsidiary began the double-blind, placebo-controlled, U.S. Phase II SEP361-203 trial to evaluate 25, 50 and 75 mg SEP-363856 once daily for 6 weeks ...